Capricor Therapeutics (NASDAQ:CAPR) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.27, Fidelity Earnings reports. The company had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.22 million. Capricor Therapeutics had a negative return on equity of 270.78% and a negative net margin of 794.63%.
Shares of NASDAQ:CAPR traded down $0.31 during midday trading on Friday, reaching $2.20. The company had a trading volume of 121,100 shares, compared to its average volume of 285,875. Capricor Therapeutics has a 1-year low of $2.01 and a 1-year high of $10.70. The business’s 50 day moving average price is $2.81 and its 200 day moving average price is $2.63. The stock has a market cap of $9.71 million, a PE ratio of -0.42 and a beta of 1.79.
A number of brokerages have recently commented on CAPR. Maxim Group restated a “hold” rating on shares of Capricor Therapeutics in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and issued a $19.50 price target on shares of Capricor Therapeutics in a report on Friday, October 11th. Zacks Investment Research upgraded Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a report on Thursday, October 31st. Finally, ValuEngine raised Capricor Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Article: Convertible Shares
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.